Selective serotonin reuptake inhibitor toxicity: Difference between revisions
(Redirected page to Serotonin syndrome) |
|||
(21 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
==Background== | |||
*Most serious adverse effect is potential to produce [[serotonin syndrome]] | |||
**However, serotonin syndrome unlikely to occur unless co-ingested with other serotonergic drug classes (MAOIs, SNRI, TCAs, amphetamines, opiates) | |||
*Pure overdoses are generally benign (mortality uncommon). Associated with less toxicity than tricyclic antidepressants. | |||
*Are the most commonly prescribed antidepressants in the United States<ref>Pirraglia PA, Stafford RS, Singer DE. Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary Care. Prim Care Companion J Clin Psychiatry. 2003 Aug;5(4):153-157. doi: 10.4088/pcc.v05n0402. PMID: 15213776; PMCID: PMC419384.</ref> | |||
*Examples include fluoxetine (Prozac), paroxetine (Paxil), fluvoxamine (Luvox), sertraline (Zoloft), escitalopram (Lexapro), and citalopram (Celexa) | |||
*Citalopram (>600 mg) and escitalopram (>300mg) are unique, as they may cause dose dependent [[QT prolongation]] and increase risk of [[torsades de pointes]] | |||
==Clinical Features== | |||
*'''Symptoms''' | |||
**[[Nausea and vomiting]] | |||
**[[Agitation]] | |||
**[[Ataxia]] | |||
**[[Confusion]] | |||
*'''Signs''' | |||
**[[Altered mental status]] | |||
**Autonomic instability | |||
***Diaphoresis | |||
***[[Hyperthermia]] | |||
***[[Hypertension]]/[[hypotension]] | |||
***[[Sinus tachycardia]] | |||
**Neuromuscular hyperactivity | |||
***Hyperreflexia | |||
***Muscular rigidity | |||
***Resting tremor | |||
==Differential Diagnosis== | |||
*[[Serotonin syndrome]] | |||
*[[Neuroleptic Malignant Syndrome]] | |||
*[[Acetaminophen Toxicity]] | |||
*Withdrawal Syndromes | |||
*[[Encephalitis]] | |||
*[[Heatstroke]] | |||
*[[Hyperthyroidism]] | |||
*[[Meningitis]] | |||
*[[Rhabdomyolysis]] | |||
*[[Tetanus]] | |||
{{Anticholinergic types}} | |||
==Evaluation== | |||
===Workup=== | |||
*[[ECG]] | |||
**QRS, [[QT prolongation]] (citalopram only) | |||
===Diagnosis=== | |||
==Management== | |||
*Treatment is mostly supportive. Consult poison control for guidance, if needed. | |||
*Administer [[activated charcoal]] if lethal amount ingested within 1-2 hours | |||
*Continuous cardiac monitoring required for citalopram (>600 mg) and escitalopram (>300mg) for at least 8 hours. | |||
**If citalopram (>1000 mg) and escitalopram (>500 mg) has been ingested then monitor for 12-24 hours | |||
***[[Magnesium]] sulfate 2g IV if QTc > 500 msec | |||
*Manage [[seizures]] with [[benzodiazepines]] | |||
*Manage [[hyperthermia]] | |||
*If suspecting [[Serotonin Syndrome]], stop all serotonergic medication: | |||
**SSRIs | |||
**Anticonvulsants (valproate) | |||
**Antiemetics (ondansetron, metoclopramide) | |||
**Analgesics (fentanyl, tramadol, methadone) | |||
**Antibiotics (linezolid) | |||
==Disposition== | |||
*Consider admission for patients who are tachycardic or lethargic 6hr after ingestion | |||
*ECG before clearing a patient with citalopram ingestion | |||
==See Also== | |||
*[[Serotonin syndrome]] | |||
*[[SNRI Toxicity]] | |||
==External Links== | |||
*[https://litfl.com/ssri-toxicity/ Life in the Fast Lane (LITFL) - SSRI Toxicity] | |||
==References== | |||
<references/> | |||
[[Category:Toxicology]] |
Latest revision as of 21:21, 6 July 2022
Background
- Most serious adverse effect is potential to produce serotonin syndrome
- However, serotonin syndrome unlikely to occur unless co-ingested with other serotonergic drug classes (MAOIs, SNRI, TCAs, amphetamines, opiates)
- Pure overdoses are generally benign (mortality uncommon). Associated with less toxicity than tricyclic antidepressants.
- Are the most commonly prescribed antidepressants in the United States[1]
- Examples include fluoxetine (Prozac), paroxetine (Paxil), fluvoxamine (Luvox), sertraline (Zoloft), escitalopram (Lexapro), and citalopram (Celexa)
- Citalopram (>600 mg) and escitalopram (>300mg) are unique, as they may cause dose dependent QT prolongation and increase risk of torsades de pointes
Clinical Features
- Symptoms
- Signs
- Altered mental status
- Autonomic instability
- Diaphoresis
- Hyperthermia
- Hypertension/hypotension
- Sinus tachycardia
- Neuromuscular hyperactivity
- Hyperreflexia
- Muscular rigidity
- Resting tremor
Differential Diagnosis
- Serotonin syndrome
- Neuroleptic Malignant Syndrome
- Acetaminophen Toxicity
- Withdrawal Syndromes
- Encephalitis
- Heatstroke
- Hyperthyroidism
- Meningitis
- Rhabdomyolysis
- Tetanus
Anticholinergic toxicity Causes
- Medications[2]
- Atropine
- Antihistamines
- Antidepressants
- Antipsychotics
- Muscle relaxants
- Anti-Parkinsonians
- Plants
- Jimson weed (Devil's trumpet)
- Amanita mushroom
Evaluation
Workup
- ECG
- QRS, QT prolongation (citalopram only)
Diagnosis
Management
- Treatment is mostly supportive. Consult poison control for guidance, if needed.
- Administer activated charcoal if lethal amount ingested within 1-2 hours
- Continuous cardiac monitoring required for citalopram (>600 mg) and escitalopram (>300mg) for at least 8 hours.
- If citalopram (>1000 mg) and escitalopram (>500 mg) has been ingested then monitor for 12-24 hours
- Magnesium sulfate 2g IV if QTc > 500 msec
- If citalopram (>1000 mg) and escitalopram (>500 mg) has been ingested then monitor for 12-24 hours
- Manage seizures with benzodiazepines
- Manage hyperthermia
- If suspecting Serotonin Syndrome, stop all serotonergic medication:
- SSRIs
- Anticonvulsants (valproate)
- Antiemetics (ondansetron, metoclopramide)
- Analgesics (fentanyl, tramadol, methadone)
- Antibiotics (linezolid)
Disposition
- Consider admission for patients who are tachycardic or lethargic 6hr after ingestion
- ECG before clearing a patient with citalopram ingestion
See Also
External Links
References
- ↑ Pirraglia PA, Stafford RS, Singer DE. Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary Care. Prim Care Companion J Clin Psychiatry. 2003 Aug;5(4):153-157. doi: 10.4088/pcc.v05n0402. PMID: 15213776; PMCID: PMC419384.
- ↑ Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium – theory, evidence and practice. Br J Clin Pharmacol. 2015;81(3):516-24.